Abstract: An artificial placenta oxygenating device for use with an infant is provided. The device comprises a first layer comprising a gas permeable membrane; and a second layer comprising a vascular network that permits circulation of fluid therethrough, wherein a portion of the gas permeable membrane is attached to and covers the vascular network, wherein the vascular network comprises an inlet that permits fluid flow into the vascular network and an outlet that permits fluid to flow out of the vascular network and wherein the inlet and outlet are positioned so that fluid flows through the vascular network and in contact with the gas permeable membrane to permit gas exchange to occur. Assemblies comprising a plurality of single artificial placenta devices is also provided.

Abstract: A method comprising providing an indication that a purchasable is for sale by a seller to an online sales platform connected to a communication network. Buyer data is provided for a plurality of buyers and is indicative of online shopping behavior of each of the buyers. A first group and second group of buyers is selected from the plurality of buyers in dependence on the buyer data. A first offer of sale of the purchasable is provided to each buyer of the first group of buyers and not to any other buyers. If a request to purchase the purchasable is received from one of the buyers of the first group of buyers the purchasable is sold to the one of the buyers of the first group. If a request to purchase the purchasable is not received from one of the buyers of the first group of buyers a second offer of sale of the purchasable is automatically provided to each buyer of the second group.

Abstract: An artificial placenta oxygenating device for use with an infant is provided. The device comprises a first layer comprising a gas permeable membrane; and a second layer comprising a vascular network that permits circulation of fluid therethrough, wherein a portion of the gas permeable membrane is attached to and covers the vascular network, wherein the vascular network comprises an inlet that permits fluid flow into the vascular network and an outlet that permits fluid to flow out of the vascular network and wherein the inlet and outlet are positioned so that fluid flows through the vascular network and in contact with the gas permeable membrane to permit gas exchange to occur. Assemblies comprising a plurality of single artificial placenta devices is also provided.

Abstract: The invention relates generally to a coating composition for a polymeric surface, methods for coating a polymeric surface, methods for preparing coated medical devices, polymeric surfaces coated with the coating composition, and medical devices comprising the coating composition. In particular, a coating composition for association with a polymeric surface, preferably a polymeric surface of a medical device, is described comprising a cross-linked basecoat displaying a plurality of active groups in association with a serpin or serpin derivatives, wherein the serpin or serpin derivatives are not substantially cross-linked with other serpin or serpin derivatives.

Abstract: Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome, and on surfaces in contact with blood are also described.

Abstract: Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome are also described.

Abstract: Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome are also described.

Abstract: Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome, and on surfaces in contact with blood are also described.